April 23, 2018 04:29 PM EDT
Deals
R&D

Bank­rupt and weary, di­et pill mak­er Orex­i­gen to sell for $75M to Nal­pro­pi­on

Brittany Meiling

Di­et pill mak­er Orex­i­gen Ther­a­peu­tics can fi­nal­ly turn out the lights. Af­ter a years-long bat­tle to bring its fi­nances in­to the black, the com­pa­ny put …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times